Overview

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Status:
Recruiting
Trial end date:
2028-04-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC